Heartcore Capital

Founder and managing partner Jimmy Fussing Nielsen leads the firm's investment committee, supported by partners Christian Lindener in Berlin and Max Niederhofer. The partnership structure keeps decision-making concentrated across a small senior team, with each partner holding sector-specific mandates and geographic coverage across the Nordics, DACH, and France.

The firm sources through a combination of its fund-of-funds program — which commits to other European seed managers and surfaces early deal intelligence — and the deep founder networks its partners have built over fifteen years in the Nordic and German ecosystems. Nielsen's role as a co-founder of the Nordic venture community and the firm's multi-city office structure give it access to pre-institutional rounds that later-stage funds overlook.

Heartcore operates as a classic venture capital firm managing institutional limited-partner capital, not as a family office. Its funds are backed by European institutional investors, fund-of-funds, and family offices. The firm charges management fees and carried interest under a standard European venture fund structure.

Heartcore runs a dedicated fund-of-funds program alongside its direct investment activity. The fund-of-funds sleeve commits capital to other European seed-stage venture managers, which the firm uses as both a return driver and a deal-sourcing pipeline into adjacencies where Heartcore itself does not lead rounds.

The firm focuses on seed and Series A, with initial checks ranging from EUR 1 million to EUR 10 million. Heartcore reserves significant capital for follow-on investments through Series B, allowing it to maintain pro-rata in breakout portfolio companies. It does not compete for large growth-stage rounds.

Heartcore is the direct successor to Sunstone Technology Ventures, the tech-investing arm of the Danish firm Sunstone Capital. In 2018, Sunstone formally separated its technology and life-science practices into two independent firms. The tech practice rebranded as Heartcore Capital under Jimmy Fussing Nielsen's continued leadership, while the life-science practice remained under the Sunstone name.

Heartcore does not invest in life sciences, hardtech requiring massive capital expenditure, or deep-tech with multi-decade commercialization timelines. The firm's explicit separation from Sunstone in 2018 was partly to draw a clean line away from biotech and therapeutics, keeping the portfolio concentrated in capital-efficient software and consumer-internet companies.